Outcome of Board Meeting held on 25th May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.0 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fredun Pharmaceuticals reported strong full-year FY2026 results with standalone revenue growing 40% to Rs 63,912 lakhs from Rs 45,627 lakhs, and PAT jumping 60% to Rs 3,321 lakhs from Rs 2,081 lakhs. EPS stood at Rs 68.01. The Board approved a 2:1 bonus share issue (2 bonus shares for every 1 held), a 70 paise per share final dividend, and increased authorised share capital from Rs 10 crore to Rs 50 crore. Auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The only audit observation was a delay in transferring unclaimed dividends to IEPF, which does not qualify the opinion.
Strong revenue and profit growth is positive for shareholders, though the 75% jump in finance costs and near 5x increase in long-term borrowings to Rs 5,631 lakhs warrants monitoring. The bonus issue and dividend signal management confidence, though existing shareholders face dilution.